FDA Clearance Tracker · DEN250026
Avulux
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 21, 2026
De Novo granted
Time to decision
424 days
Received Jun 23, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class I
The decision
- FDA number
- DEN250026
- Device name
- Avulux
- Applicant
- Matap Ii, LLC
- Applicant location
- Aventura, FL
- Received
- Jun 23, 2025
- Decided
- Aug 21, 2026
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class I
- Regulation
- 21 CFR 882.5811
- Specialty
- Neurology & Neurosurgery
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN250026
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Matap Ii, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.